Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database

Abstract Aim Real‐world data (RWD) for paliperidone palmitate (PP) three‐monthly (PP3M) is lacking based on Japan label requirements. This study evaluated the clinical effectiveness of PP3M versus PP once‐monthly (PP1M) in patients with schizophrenia administered according to Japan label requirement...

Full description

Saved in:
Bibliographic Details
Main Authors: Chih‐Lin Chiang, Madoka Chinen, Mehmet Daskiran, Akihide Wakamatsu, Ibrahim Turkoz
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Neuropsychopharmacology Reports
Subjects:
Online Access:https://doi.org/10.1002/npr2.12473
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items